23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort.
23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.
Watera
Christine
C
MRC Programme on AIDS, Entebbe, Uganda.
Nakiyingi
Jessica
J
Miiro
George
G
Muwonge
Richard
R
Whitworth
James A G
JA
Gilks
Charles F
CF
French
Neil
N
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D000328:Adult; D015331:Cohort Studies; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000401:mortality; D006801:Humans; D022242:Pneumococcal Vaccines; D011024:Pneumonia, Viral / Q000150:complications / Q000401:mortality / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D014454:Uganda / Q000453:epidemiology
D022242:Pneumococcal Vaccines